Inhibitors of neprilysin: design, pharmacological and clinical applications.
作者信息
Roques B P, Noble F, Crine P, Fournié-Zaluski M C
机构信息
Département de Pharmacochimie Moléculaire et Structurale, Institut National de la Santé et de la Recherche Medicale, Centre National de la Recherche Scientifique, Université René Descartes, Paris, France.
出版信息
Methods Enzymol. 1995;248:263-83. doi: 10.1016/0076-6879(95)48019-6.
PMID:7674926
Abstract
摘要
相似文献
1
Inhibitors of neprilysin: design, pharmacological and clinical applications.
Methods Enzymol. 1995;248:263-83. doi: 10.1016/0076-6879(95)48019-6.
2
"Atriopeptidase" (EC 3.4.24.11) inhibition and protection of atrial natriuretic factor.
Adv Nephrol Necker Hosp. 1994;23:233-46.
3
Phosphonamide inhibitors of neutral endopeptidase (EC 3.4.24.11).
J Enzyme Inhib. 1997 Apr;12(1):71-7. doi: 10.3109/14756369709027665.
4
Optimal recognition of neutral endopeptidase and angiotensin-converting enzyme active sites by mercaptoacyldipeptides as a means to design potent dual inhibitors.
J Med Chem. 1996 Mar 15;39(6):1210-9. doi: 10.1021/jm950590p.
5
6
Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities.
J Med Chem. 2000 Apr 6;43(7):1398-408. doi: 10.1021/jm990483l.
7
A computational approach to the study of the binding mode of dual ACE/NEP inhibitors.
J Chem Inf Model. 2010 Mar 22;50(3):388-96. doi: 10.1021/ci9005047.
8
Kallidin- and bradykinin-degrading pathways in human heart: degradation of kallidin by aminopeptidase M-like activity and bradykinin by neutral endopeptidase.
Circulation. 1999 Apr 20;99(15):1984-90. doi: 10.1161/01.cir.99.15.1984.
9
Neutral endopeptidase inhibitors and atrial natriuretic peptide.
J Clin Pharmacol. 1991 Aug;31(8):758-62. doi: 10.1002/j.1552-4604.1991.tb03773.x.
10
Dual metalloprotease inhibitors. 6. Incorporation of bicyclic and substituted monocyclic azepinones as dipeptide surrogates in angiotensin-converting enzyme/neutral endopeptidase inhibitors.
J Med Chem. 1996 Jan 19;39(2):494-502. doi: 10.1021/jm950677a.
引用本文的文献
1
Neprilysin impedes islet amyloid formation by inhibition of fibril formation rather than peptide degradation.
J Biol Chem. 2010 Jun 11;285(24):18177-83. doi: 10.1074/jbc.M109.082032. Epub 2010 Apr 16.
2
Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.
Med Res Rev. 2006 Jan;26(1):88-130. doi: 10.1002/med.20044.
3
Interaction of mammalian neprilysin with binding protein and calnexin in Schizosaccharomyces pombe.
Biochem J. 1999 Jun 15;340 ( Pt 3)(Pt 3):813-9.
Zotero 插件